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Abstract. 
 
Dentato-rubral and pallido-luysian atrophy 
(DRPLA) is one of the family of neurodegenerative 
diseases caused by expansion of a polyglutamine tract. 
 
The 
 
drpla
 
 gene product, atrophin-1, is widely ex-
pressed, has no known function or activity, and is found 
in both the nuclear and cytoplasmic compartments of 
neurons. Truncated fragments of atrophin-1 accumulate 
in neuronal nuclei in a transgenic mouse model of 
DRPLA, and may underlie the disease phenotype.
Using the yeast two-hybrid system, we identified 
ETO/MTG8, a component of nuclear receptor core-
pressor complexes, as an atrophin-1–interacting
protein. When cotransfected into Neuro-2a cells, atro-
phin-1 and ETO/MTG8 colocalize in discrete nuclear 
structures that contain endogenous mSin3A and his-
tone deacetylases. These structures are sodium dodecyl 
sulfate–soluble and associated with the nuclear matrix. 
Cotransfection of ETO/MTG8 with atrophin-1 recruits 
atrophin-1 to the nuclear matrix, while atrophin-1 and 
ETO/MTG8 cofractionate in nuclear matrix prepara-
tions from brains of DRPLA transgenic mice. Further-
more, in a cell transfection–based assay, atrophin-1 re-
presses transcription. Together, these results suggest 
that atrophin-1 associates with nuclear receptor core-
pressor complexes and is involved in transcriptional 
regulation.
Emerging links between disease-associated poly-
glutamine proteins, nuclear receptors, translocation-
leukemia proteins, and the nuclear matrix may have
important repercussions for the pathobiology of this 
family of neurodegenerative disorders.
Key words: trinucleotide repeats • neurodegenerative 
diseases • cerebellar nuclei • nuclear matrix • myeloid 
leukemia
 
Introduction
 
Dentato-rubral and pallido-luysian atrophy (DRPLA)
 
1
 
 is
one of at least eight neurodegenerative disorders caused
by the expansion of a polyglutamine tract within a disease-
associated protein (Ross, 1995; Gusella and MacDonald,
1996; Paulson and Fischbeck, 1996). There is a critical
 
threshold for disease at 
 
z
 
40 glutamines; expansion of the
polyglutamine tract beyond this threshold gives a neuro-
toxic protein. The mechanisms underlying neurotoxicity
are not fully understood. The DRPLA gene product, atro-
phin-1, has no known function or biological activity, and is
found in both the nuclear and cytoplasmic compartments
of neurons (Yazawa et al., 1995; Schilling et al., 1999).
Truncated fragments of atrophin-1, containing the ex-
panded polyglutamine tract, have been shown to accumu-
late in populations of neuronal nuclei, both in a transgenic
mouse model of DRPLA and in human postmortem
DRPLA patient brain tissue (Schilling et al., 1999). These
fragments may underlie the pathogenesis of DRPLA.
There is evidence to suggest that the nucleus may be the
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primary site of cellular dysfunction in other members of
this family of diseases (Klement et al., 1998; Saudou et al.,
1998). Polyglutamine-containing proteins have an inherent
ability to aggregate when the length of the polyglutamine
tract exceeds the aforementioned critical threshold (Scher-
zinger et al., 1997). The threshold for aggregation closely
correlates with the threshold for disease, and neuronal
intranuclear inclusion bodies have been identified as a
pathological hallmark in these disorders (Ross, 1997). Nu-
clear inclusions are macromolecular structures, some of
which are ubiquitinated, and contain molecular chaper-
ones and components of the proteasome in addition to the
expanded polyglutamine protein (Cummings et al., 1998;
Chai et al., 1999). Other nuclear proteins that contain
glutamine repeats, such as TATA-binding protein and
CREB-binding protein (CBP; Kazantsev et al., 1999) can
be recruited into these structures (Perez et al., 1998). It is
not clear whether the inclusions are directly neurotoxic. In
the cases of huntingtin and ataxin-1, it has been suggested
that nuclear localization of the mutant protein is more im-
portant than the presence of macromolecular aggregates
in determining neurotoxicity (Klement et al., 1998; Saudou
et al., 1998). Whether aggregation is critical or not, the nu-
cleus is strongly implicated as a major site of neuronal dys-
function.
As truncated fragments of atrophin-1 accumulate in
neuronal nuclei in a transgenic mouse model of DRPLA,
we have sought to identify nuclear processes in which atro-
phin-1 is involved. Using the yeast two-hybrid system, we
now demonstrate that atrophin-1 interacts with a protein
known as ETO/MTG8. ETO/MTG8 is a member of a fam-
ily of highly conserved proteins, and was first identified as
the fusion partner with AML1 in t(8;21) acute myeloid
leukemia (Erickson et al., 1992; Nisson et al., 1992; Mi-
yoshi et al., 1993). The ETO/MTG8 moiety of the chimeric
AML1-ETO/MTG8 fusion diverts the AML1 moiety from
AML1 subnuclear domains (McNeil et al., 1999) and re-
cruits the nuclear receptor corepressor (N-CoR)/mSin3/
histone deacetylase (HDAC) complex (Gelmetti et al.,
1998; Lutterbach et al., 1998b; Wang et al., 1998a), acting
to repress transcription and to disturb hematopoietic cell
differentiation. ETO/MTG8 and its 
 
Drosophila
 
 homologue,
nervy, are normally expressed in brain tissue. Here we
demonstrate colocalization and cofractionation of ETO/
MTG8 and atrophin-1 in discrete nuclear matrix-asso-
ciated structures. Furthermore, atrophin-1 (like ETO/
MTG8) can repress transcription when assessed in tran-
sient reporter assays. We hypothesize that nuclear accu-
mulation of truncated atrophin-1 fragments in DRPLA
may interfere with transcriptional control and thus con-
tribute to disease progression.
 
Materials and Methods
 
Yeast Two-hybrid Screening
 
Nucleotides 76–1438 of atrophin-1 (encoding lysine 2 to asparagine 455)
were amplified by PCR using EXPAND high fidelity enzyme mix (Roche)
using the following primers: 5
 
9
 
-ACGTCGACCCTGAAGACACGACA-
GAATA-3
 
9
 
 and 5
 
9
 
-GGAGTTTAGCGGCCGCTTAATTGCTGTTGG-
CTAA-3
 
9
 
, and pCDNA3-At-FL-26Q as template. The PCR product was
digested with SalI and NotI and ligated into the GAL4 DNA-binding do-
main (DBD) vector pPC97 (Chevray and Nathans, 1992). DNA sequenc-
 
ing confirmed in-frame fusion of atrophin-1 to the GAL4 DBD. The re-
sulting vector, pPC97-At-2-455, was cotransformed into yeast strain
Y190 with the GAL4 activation domain vector pPC86 (Chevray and
Nathans, 1992) to confirm that it did not activate the His and 
 
b
 
-galac-
tosidase reporter genes in the absence of an interaction partner. pPC97-
At-2-455 was used to screen a human cerebellum cDNA library in
pPC86 as described elsewhere (Wood et al., 1998). The library plasmids
were isolated from His
 
1
 
/
 
b
 
-gal
 
1
 
 colonies, retransformed into Y190 with
pPC97-At-2-455 to confirm isolation of putative interactors, and se-
quenced.
 
Immunoaffinity Purification of Atrophin-1
 
Antibody APG840 was raised against synthetic peptide DRPLA-425 cor-
responding to residues 425–439 of human atrophin-1 at Cocalico Biolo-
gicals Inc., Reamstown, PA. This peptide is 100% conserved between hu-
man and mouse and was previously used to produce antibody AP142 in
rabbit (Wood et al., 1998). Antibodies were purified from serum on a Sul-
foLink–DRPLA-425 column and coupled to CarboLink gel (Pierce
Chemical Co.). Brain extracts were prepared by homogenizing mouse
brains in 10 vol of PBS supplemented with 0.5% Igepal CA-630, 1 mM
PMSF, and complete protease inhibitor cocktail (Roche) followed by cen-
trifugation at 10,000 
 
g
 
 for 10 min at 4
 
8
 
C. Atrophin-1 was immunoaffinity
purified from brain extracts with 100 
 
m
 
g of APG840 coupled to 400 
 
m
 
l of
CarboLink gel. Control immunoaffinity purifications were performed
with 200 
 
m
 
g of goat IgG coupled to 400 
 
m
 
l of CarboLink gel. Purified com-
plexes were washed three times with homogenization buffer and analyzed
by immunoblotting with anti–atrophin-1 antibody AP142 and anti-ETO/
MTG8 antibody 2174 (Sacchi et al., 1998).
 
Cell Transfection and Immunofluorescence Microscopy
 
Neuro-2a cells were cultured in 1:1 DMEM/OPTI-MEM I supplemented
with 5% FBS and antibiotics. For immunofluorescence microscopy, cells
were transiently transfected in 4-well chamber slides with various combi-
nations of pCDNA3, pCDNA3-At-FL-26Q, pCDNA3-At-FL-65Q, and
pCDNA3-FLAG-ETO/MTG8 (total 0.2 
 
m
 
g DNA/well) using Lipo-
fectamine PLUS (Life Technologies). 24 h after transfection, they were
fixed in 3:1 methanol/acetone for 10 min at 
 
2
 
20
 
8
 
C. Immunostaining was
performed using rabbit polyclonal anti–atrophin-1 antibody AP142
(Wood et al., 1998), goat polyclonal anti–atrophin-1 antibody APG840,
mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich), goat poly-
clonal antihistone deacetylase 1 (HDAC1) antibody C-19, goat polyclonal
antihistone deacetylase 2 (HDAC2) antibody C-19, rabbit polyclonal anti-
mSin3A antibody AK-11, goat polyclonal anti–N-CoR antibody C-20,
mouse monoclonal anti–promyelocytic leukemia protein (PML) antibody
PG-M3 (all from Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti-
PML antibody (a kind gift from Robert Redner, University of Pittsburgh,
Pittsburgh, PA), and rabbit polyclonal antiubiquitin antibody (Dako).
FITC- and Cy3-labeled secondary antibodies (all from donkey) were from
Jackson ImmunoResearch Laboratories. Immunofluorescence was ob-
served using a Zeiss LSM 410 confocal imaging microscope.
 
Immunoblotting
 
Neuro-2a cells were cultured in 10-cm-diameter culture dishes and trans-
fected with various combinations of pCDNA3, pCDNA3-At-FL-26Q,
pCDNA3-At-FL-65Q, and pCDNA3-FLAG-ETO/MTG8 (total 10 
 
m
 
g
DNA/well) using Lipofectamine PLUS (Life Technologies). 24 h after
transfection, they were washed once with PBS and scraped into 0.5 ml of
20 mM Hepes (pH 7.4), 150 mM NaCl, 0.5% Triton X-100, and 1 mM
PMSF, supplemented with complete protease inhibitor cocktail (Roche).
An equal volume of 2
 
3
 
 Laemmli sample buffer was then added, and the
samples were heated at 70
 
8
 
C for 5 min, sonicated for 20 s, and microfuged
for 1 min before loading. Proteins were resolved in a 4–15% polyacryl-
amide gel and immunoblotted for atrophin-1 with AP142 and FLAG-
ETO/MTG8 with monoclonal antibody M2.
 
Nuclear Matrix Preparation
 
For immunoblot analysis of transfected cells, Neuro-2a cells were cultured
in 10-cm dishes and transfected as above, then washed once with PBS and
harvested 24 h after transfection by scraping into 1 ml of 10 mM Pipes (pH
6.8), 300 mM sucrose, 100 mM NaCl, 3 mM MgCl
 
2
 
, 1 mM EGTA, 0.5%
Triton X-100, 1 mM PMSF, 2 mM vanadyl ribonucleoside complex
(VRC), and 1
 
3
 
 EDTA-free complete protease inhibitor cocktail. The cell
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pellet was collected by low-speed centrifugation and extracted sequen-
tially with (i) 10 mM Pipes (pH 6.8), 250 mM ammonium sulfate, 300 mM
sucrose, 3 mM MgCl
 
2
 
, 1 mM EGTA, 1 mM PMSF, 2 mM VRC, and 1
 
3
 
EDTA-free complete protease inhibitor cocktail; (ii) 10 mM Pipes (pH
6.8), 300 mM sucrose, 50 mM NaCl, 3 mM MgCl
 
2
 
, 1 mM EGTA, 0.5% Tri-
ton X-100, 200 U/ml DNase I, 1 mM PMSF, 2 mM VRC, and 1
 
3
 
 EDTA-
free complete protease inhibitor cocktail; and (iii) 10 mM Pipes (pH 6.8),
300 mM sucrose, 2 M NaCl, 3 mM MgCl
 
2
 
, 1 mM EGTA, 1 mM PMSF, 2
mM VRC, and 1
 
3
 
 EDTA-free complete protease inhibitor cocktail. All
extractions were for 5 min at 4
 
8
 
C except for DNase I, digestion which was
performed at 32
 
8
 
C for 30 min. Nuclear matrices were resuspended in 1 ml
of SDS-PAGE sample buffer, heated at 70
 
8
 
C for 5 min, and then soni-
cated for 20 s. Volumetric equivalents of the supernatants from each ex-
traction were immunoblotted for atrophin-1 and FLAG-ETO/MTG8 with
antibodies AP142 and M2.
For nuclear matrix preparations from brain, nuclei were isolated from
DRPLA transgenic mice as described elsewhere (Schilling et al., 1999),
and the nuclear matrix was prepared from the isolated nuclei following
the same protocol as for transfected cells, except that the final wash with 2
M NaCl was omitted. The subnuclear fractions were immunoblotted for
atrophin-1 and ETO/MTG8 with antibodies AP142 (Wood et al., 1998)
and 2174 (Sacchi et al., 1998).
For immunocytochemistry of isolated nuclear matrix preparations,
Neuro-2a cells were grown in 2-well chamber slides and transfected with
atrophin-1 and FLAG-ETO/MTG8 cDNAs using Lipofectamine PLUS.
24 h after transfection, cells were rinsed with PBS and subjected to the se-
ries of extractions described above. After the final extraction, nuclear ma-
trices were rinsed with PBS then fixed with 4% paraformaldehyde in PBS
and stained with anti–atrophin-1 antibody APG840 and anti-FLAG M2
monoclonal antibody.
 
Transcriptional Assays
 
Full-length atrophin-1 cDNAs, encoding 26 and 65 consecutive gluamines,
respectively, were amplified by PCR using EXPAND high fidelity enzyme
mix (Roche) with the following primers: 5
 
9
 
-GCTCTAGAAATGA-
AGACACGACAGAAT-3
 
9
 
 and 5
 
9
 
-CGGGGTACCGGGGTGCTCCA-
AGGTCCAAT-3
 
9
 
, and pCDNA3-At-FL-26Q and pCDNA3-At-FL-65Q
as templates. The products were digested with XbaI and KpnI and ligated
into the eukaryotic GAL4 DBD fusion protein expression vector pFA–
CMV. DNA sequencing confirmed in-frame fusion of atrophin-1 to the
GAL4 DBD and the lengths of the glutamine repeats. Immunoblotting of
transfected cell extracts confirmed expression of GAL4–atrophin-1 pro-
teins.
To demonstrate dose-dependent transcriptional repression by atro-
phin-1, 0.1-1.0 
 
m
 
g of GAL4 DNA-binding construct with empty pFA–
CMV to a total of 1 
 
m
 
g was transfected into Neuro-2a cells cultured in
6-well plates using Lipofectamine PLUS (Life Technologies). To demon-
strate enhancement of atrophin-1–mediated repression by ETO/MTG8,
0.33 
 
m
 
g of pFA-At26/65Q was cotransfected with 0.5 
 
m
 
g of CDNA3 or
pCDNA3-FLAG-ETO/MTG8. In all cases, 1 
 
m
 
g of a luciferase reporter
plasmid containing four GAL4-binding sites upstream of a thymidine ki-
nase promoter, and 0.1 
 
m
 
g of a 
 
b
 
-galactosidase expression plasmid (CMV
promoter) as an internal control for transfection efficiency, were cotrans-
fected into each well. Cells were harvested 24 h after transfection into
Reporter Lysis Buffer (Promega). Luciferase activity was normalized to
 
b
 
-galactosidase activity. The results shown in Fig. 4 are the mean of three
independent transfections. Error bars indicate standard deviations. Con-
sistent results were obtained with multiple DNA preparations.
 
Results
 
Identification of ETO/MTG8 as an
Atrophin-1–interacting Protein
 
3 
 
3
 
 10
 
5
 
 clones of a human cerebellum cDNA library in
pPC86 were screened with pPC97-At-2-455. Seven His
 
1
 
/
 
b
 
-gal
 
1
 
 secondary positives were obtained. All encoded
known proteins. Five encoded the ETO/MTG8 oncopro-
tein (Fig. 1 A), one encoded a portion of the related onco-
protein MTG16 (Fig. 1 A), and the last encoded a portion
of WWP1, a protein previously shown to interact with at-
rophin-1 (Wood et al., 1998). The largest ETO/MTG8 clone
(S9) was used for further characterization of the interac-
tion with atrophin-1. pPC86-ETO/MTG8(S9) was cotrans-
fected into Y190 with pPC97 containing no insert; pPC97
containing cDNA encoding residues 1–598 of the Hunting-
ton’s disease gene product, huntingtin (with both 18 and
81 glutamines); and various pPC97 atrophin-1 constructs
(encoding amino acids 2–455, 413–731 with 26Q, 413–731
with 65Q, 640–1184, 2–1184 with 26Q, and 2–1184 with
65Q respectively). Only yeast cotransformed with ETO/
MTG8 and the NH
 
2
 
 terminus of atrophin-1 or full-length
atrophin-1 constructs were His
 
1
 
/
 
b
 
-gal
 
1
 
, demonstrating
that ETO/MTG8 interacts specifically with the NH
 
2
 
 termi-
nus of atrophin-1 (Fig. 1 B). There was no discernible dif-
ference in the strength of the interaction of ETO/MTG8
with the 26 or 65 glutamine forms of atrophin-1.
To confirm that atrophin-1 and ETO/MTG8 coexist in
physiologically relevant complexes, atrophin-1 was immu-
noaffinity purified from mouse brain using goat polyclonal
anti–atrophin-1 antibody APG840 immobilized on a solid
support. Immunoblotting with rabbit polyclonal anti–atro-
phin-1 antibody AP142 (Wood et al., 1998) confirmed suc-
cessful immunopurification of atrophin-1 (Fig. 1 C, left),
while immunoblotting with rabbit polyclonal ETO/MTG8
antibody 2174 (Sacchi et al., 1998) demonstrated coim-
munopurification of ETO/MTG8 with atrophin-1 (Fig. 1
C, right). Control immunoaffinity purifications were per-
formed with goat IgG coupled to the same support matrix.
 
Atrophin-1 and ETO/MTG8 Colocalize in Discrete 
Nuclear Structures
 
To determine whether atrophin-1 and ETO/MTG8 colo-
calize in cells, full-length cDNA expression constructs for
atrophin-1 and FLAG-ETO/MTG8 were cotransfected
into Neuro-2a cells. Transfected cells were immunostained
simultaneously with the anti–atrophin-1 rabbit polyclonal
antibody AP142 and the anti-FLAG M2 monoclonal anti-
body. Atrophin-1 was observed in both a diffuse pattern of
small nuclear dots (Fig. 2, a and c) and larger discrete nu-
clear structures (Fig. 2, b and d). DAPI counterstaining
confirmed nuclear localization of these structures (results
not shown). Confocal imaging microscopy clearly demon-
strated colocalization of atrophin-1 and FLAG-ETO/
MTG8 in many of the large discrete subnuclear structures
(Fig. 2, b and d). Overlap of atrophin-1 and ETO/MTG8 in
the small nuclear dots was also observed, but the diffuse
nature of both signals makes it difficult to ascertain whether
this represents true colocalization. One explanation for
the observed variations in staining patterns between cells
is variation in the expression levels between cells. A
blinded observer (Table I) scored the percentage of trans-
fected cells showing each pattern of staining, or a combi-
nation of these staining patterns. A greater percentage of
cells had the large nuclear bodies when ETO/MTG8 was
cotransfected with atrophin-1 than when atrophin-1 was
cotransfected with pCDNA3 containing no insert. This
suggests that ETO/MTG8 helps recruit atrophin-1 to the
large subnuclear structures. There were no significant dif-
ferences between At-FL-26Q and At-FL-65Q transfected
cells, or At-FL-26Q plus ETO/MTG8 and At-FL-65Q plus
ETO/MTG8 transfected cells.
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Immunohistochemical analysis of atrophin-1 transgenic
and nontransgenic mouse brains with the anti–atrophin-1
antibody AP142 revealed the presence of structures simi-
lar to those illustrated in Fig. 2 in neuronal nuclei (Schill-
ing et al., 1999). However, we have been unable to observe
a similar pattern of nuclear staining in mouse brain
sections using the antibodies against ETO/MTG8 at our
disposal. All of the anti-ETO/MTG8 antibodies tested
showed high nonspecific background staining of brain sec-
tions and were deemed unsuitable for immunohistochem-
istry. Hence we have been unable to confirm that ETO/
MTG8 is also localized to these structures in neurons.
ETO/MTG8 is a component of the N-CoR/mSin3/HDAC
transcriptional repression complex (Gelmetti et al., 1998;
Lutterbach et al., 1998b; Wang et al., 1998a). Consistent
with this, the large nuclear structures observed in atro-
phin-1 and ETO/MTG8 cotransfected cells were labeled
with antibodies to mSin3A, HDAC1, and HDAC2 (Fig. 3
a, data not shown, and Fig. 3 b, respectively). However,
these structures were not labeled with an antibody to
N-CoR (results not shown) and immunoblotting of Neuro-
2a extracts failed to detect N-CoR in these cells (results
not shown).
The large atrophin-1– and ETO/MTG8-containing struc-
tures are similar in size and number to PML oncogenic do-
mains (PODs). A typical mammalian cell contains 
 
z
 
10–20
PODs, which are 
 
z
 
0.3–1 
 
m
 
m in diameter (Lamond and
Earnshaw, 1998). However, the atrophin-1 and ETO/
MTG8 immunoreactive nuclear structures were not la-
beled with antibodies to the PML, suggesting that they are
distinct from PODs. Labeling for endogenous murine
PML was not observed in Neuro-2a cells. To confirm that
these structures were not PODs, Neuro-2a cells were
cotransfected with atrophin-1, FLAG-ETO/MTG8, and
human PML expression constructs, then immunostained
for PML and atrophin-1 or PML and FLAG. No colocal-
ization of PML with either atrophin-1 or FLAG-ETO/
MTG8 was observed, and atrophin-1–expressing cells ap-
peared not to contain PODs. Instead, PML was localized
to either the nuclear periphery or to one or two very large
nuclear structures, which may represent coalescence of
PODs (Fig. 3, c and d). Note that PODs were readily de-
tected in neighboring cells expressing PML alone, demon-
strating that overexpression of atrophin-1 appears to in-
fluence the localization of PML. Monoclonal antibody
PG-M3 does not cross-react with mouse PML, so we have
Figure 1. Atrophin-1 inter-
acts with ETO/MTG8. (A)
Summary of data obtained
from yeast two-hybrid screen-
ing. The degree of homology
between the proteins is illus-
trated between the schemat-
ics. Lines represent clones
isolated by yeast two-hybrid
screening of a human cerebel-
lum library with pPC97-At-
2-455. P/S/T, proline/ser-
ine/threonine–rich domain;
TAF110, region with homol-
ogy to yeast transcription ac-
tivating factor 110; Pro,
proline-rich region; HHR,
hydrophobic heptad repeat; Coil, coiled-coil domain; ZnF, zinc finger-like domains. (B) ETO/MTG8 interacts specifically with the
NH2-terminal third of atrophin-1. No interaction was detected with the central portion of atrophin-1 containing the polyglutamine tract
(with either 26 or 65 glutamines), the COOH-terminal half of atrophin-1, or the NH2-terminal 598 amino acids of huntingtin (with 18 or
81 glutamines). (C) Coimmunoaffinity purification of atrophin-1 and ETO/MTG8. Atrophin-1 protein complexes were purified with
CarboLink-APG840 beads and immunoblotted for atrophin-1 (left) and ETO/MTG8 (right). Control immunoaffinity purifications
were performed with CarboLink goat IgG.
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been unable to test whether PML redistributes in neuronal
nuclei showing atrophin-1 accumulation in DRPLA trans-
genic mice.
 
Atrophin-1 Represses Transcription of a Reporter Gene
 
ETO/MTG8 has been shown to bind to the repression do-
mains of N-CoR and silencing mediator for retinoid and
thyroid hormone receptors (SMRT; Gelmetti et al., 1998;
Lutterbach et al., 1998b; Wang et al., 1998a) which form
complexes with mSin3 and histone deacetylases. We ob-
served colocalization of atrophin-1 with mSin3A, HDAC1,
and HDAC2 in transfected Neuro-2a cells in both the
presence (Fig. 3, a and b) and absence (results not shown)
of cotransfected ETO/MTG8, leading us to hypothesize
that atrophin-1 may itself be capable of influencing tran-
scription.
GAL4 DBD–atrophin-1 fusion proteins repressed tran-
scription of a luciferase reporter gene under the control of
a thymidine kinase promoter downstream of four GAL4-
binding sites in a dose-dependent manner in Neuro-2a
cells (Fig. 4 a). Repression by the GAL4 DBD–atrophin-1
fusion proteins was enhanced by cotransfection with
FLAG-ETO/MTG8 (Fig. 4 b), demonstrating a functional
interaction between atrophin-1 and ETO/MTG8. Note
that FLAG-ETO/MTG8 alone did not influence transcrip-
tion of the luciferase reporter. The length of the glutamine
repeat in atrophin-1 did not affect repression by GAL4
DBD–atrophin-1.
Figure 2. Atrophin-1 and ETO/MTG8 colocalize in large dis-
crete subnuclear structures in cotransfected Neuro-2a cells. At-
26Q plus FLAG-ETO/MTG8 (a and b) and At-65Q plus FLAG-
ETO/MTG8 (c and d) cotransfected cells were double-labeled
for atrophin-1 (green, left) and FLAG (red, center). The merged
images are illustrated on the right.
 
Table I. Quantification of Atrophin-1 and ETO/MTG8 Nuclear 
Staining Patterns
 
Transfection Diffuse/small dots Large structures Combination
 
% % %
 
At-FL-26Q only 28 
 
6
 
 8 22 
 
6
 
 2 50 
 
6
 
 7
At-FL-65Q only 32 
 
6
 
 6 18 
 
6
 
 2 50 
 
6
 
 7
ETO only 9 
 
6
 
 3 42 
 
6
 
 6 49 
 
6
 
 3
At-FL-26Q
 
1
 
ETO 6 
 
6
 
 4 49 
 
6
 
 3 45 
 
6
 
 7
At-FL-65Q
 
1
 
ETO 11 
 
6
 
 6 52 
 
6
 
 3 36 
 
6
 
 3
 
Cells were scored as having predominately small dots or diffuse labeling (Fig. 2, a and
c), predominately large structures (Fig. 2 d), or a combination of both staining patterns
(Fig. 2 b).
Figure 3. Atrophin-1– and ETO/MTG8-containing nuclear struc-
tures stain for mSin3A and histone deacetylases, but not PML. (a
and b) At-65Q and FLAG-ETO/MTG8 cotransfected Neuro-2a
cells were stained for atrophin-1 (green, left) and mSin3A (red,
center) and for atrophin-1 (red, left) and HDAC2 (green, cen-
ter). The merged images (right) show that endogenous mSin3A
and HDAC2 colocalize with transfected atrophin-1. (c and d) At-
26/65Q, FLAG-ETO/MTG8 and PML cotransfected Neuro-2a
cells were stained for atrophin-1 (green, left) and PML (red, cen-
ter). The merged images (right) show that PML does not colocal-
ize with atrophin-1. Cells expressing PML alone contained
PODs, whereas cells coexpressing atrophin-1 did not appear to
contain PODs; PML was localized to larger nuclear structures or
the nuclear periphery in the presence of atrophin-1. Similar re-
sults were obtained by double labeling for FLAG and PML.
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Atrophin-1– and ETO/MTG8-containing Nuclear 
Structures are SDS-soluble and Are Associated with the 
Nuclear Matrix
 
Expanded polyglutamine-containing proteins have an in-
herent ability to form SDS-insoluble aggregates (Scher-
zinger et al., 1997), and ubiquitinated neuronal intranuclear
inclusions are a pathological hallmark of the polygluta-
mine neurodegenerative disorders. The large atrophin-1
immunoreactive bodies we observed were not stained with
an antibody to ubiquitin (results not shown), and whole
cell extracts were immunoblotted to confirm that the large
atrophin-1 immunoreactive nuclear structures did not rep-
resent SDS-insoluble aggregates. ETO/MTG8 and atro-
phin-1 (with 26 or 65 glutamines) were completely solubi-
lized in SDS-PAGE sample buffer, whether they were
transfected alone or in combination (Fig. 5). There was no
atrophin-1 or FLAG-ETO/MTG8 immunoreactive mate-
rial at the top of the gel in any of the sample lanes. We
routinely observe atrophin-1 immunoreactive material at
the top of the gel when analyzing extracts from DRPLA
transgenic mouse brains (Schilling et al., 1999). Hence we
believe that the staining we observed represents a func-
tional nuclear domain or structure, and not SDS-insoluble
protein aggregates.
ETO/MTG8 has been shown to associate with the nu-
clear matrix (Chen et al., 1998; Le et al., 1998; McNeil et
al., 1999). We hypothesized that the large nuclear struc-
tures containing atrophin-1 and ETO/MTG8 that we ob-
served were associated with the nuclear matrix. To pro-
vide biochemical evidence for this hypothesis, nuclear
subfractionation was performed (Fig. 6 A). When trans-
fected alone into Neuro-2a cells, atrophin-1 was found to
be predominantly associated with the Triton X-100 soluble
fraction (Fig. 6 A, top two rows). A small proportion of at-
rophin-1 was detected in the nuclear matrix fraction of sin-
gle-transfected cells. When atrophin-1 was cotransfected
with ETO/MTG8, a much greater proportion of atrophin-1
was in the nuclear matrix fraction (Fig. 6 a, center two
rows). Nearly all ETO/MTG8 partitioned into the nuclear
matrix fractions of atrophin-1 and ETO/MTG8 cotrans-
fected Neuro-2a cells (Fig. 6 A, bottom two rows). There-
fore, expression of ETO/MTG8 recruited atrophin-1 to
the nuclear matrix fraction.
To confirm that the observed nuclear structures are as-
sociated with the nuclear matrix, we performed immuno-
Figure 4. Transcriptional re-
pression by atrophin-1. (a)
Dose-dependent repression
of a luciferase reporter gene
by GAL4 DBD-At26Q and
GAL4 DBD-At65Q. The lu-
ciferase reporter construct
contained four GAL4-bind-
ing sites upstream of a thy-
midine kinase promoter.
Luciferase activity was nor-
malized to b-galactosidase ac-
tivity. n 5 3 in both cases. (b)
Cotransfection of ETO/
MTG8 with GAL4 DBD-
At26/65Q enhanced repres-
sion by atrophin-1. n 5 3. Er-
ror bars represent SD.
Figure 5. Atrophin-1 and FLAG-ETO/MTG8 structures are
SDS-soluble. Neuro-2a cells were transfected with 5 mg
pCDNA3-At-26Q 1 5 mg pCDNA3 (At-26Q), 5 mg pCDNA3-
At-65Q 1 5 mg pCDNA3 (At-65Q), 5 mg pCDNA3-FLAG-
ETO/MTG8 1 5 mg pCDNA3 (ETO), 5 mg pCDNA3-At-26Q 1
5 mg pCDNA3-FLAG-ETO/MTG8 (At-26Q1ETO), 5 mg
pCDNA3-At-65Q 1 5 mg pCDNA3-FLAG-ETO/MTG8 (At-
65Q1ETO), or 10 mg pCDNA3 (mock). Total cell extracts were
immunoblotted for atrophin-1 (top) and FLAG-ETO/MTG8 (bot-
tom). No immunoreactivity was detected in the top of the wells in
any of the sample lanes with either antibody, demonstrating that
the atrophin-1/ETO structures are completely SDS-soluble.
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cytochemical staining of nuclear matrix preparations in
situ (Fig. 6 B). The large nuclear structures were associ-
ated with the matrix preparations and were clearly labeled
with antibodies to atrophin-1 and FLAG-ETO/MTG8
(Fig. 6 B). The series of extractions performed stripped
away most of the diffuse label seen after routine immuno-
cytochemical staining (Figs. 2 and 3).
Atrophin-1 and ETO/MTG8 have both been shown to
be expressed in the brain (Miyoshi et al., 1993; Nagafuchi
et al., 1994; Davis et al., 1999), and be localized, at least in
part, to neuronal nuclei (Yazawa et al., 1995; Sacchi et al.,
1998; Schilling et al., 1999). We have previously shown
that truncated fragments of atrophin-1 accumulate in neu-
ronal nuclei in a transgenic mouse model of DRPLA
(Schilling et al., 1999), while in this paper we have shown
that atrophin-1 can be recruited to the nuclear matrix by
ETO/MTG8. We reasoned that the fragments observed in
DRPLA transgenic mice might also be associated with the
nuclear matrix and we performed subfractionation of nu-
clei purified from DRPLA transgenic mice to test this hy-
pothesis (Fig. 7). Atrophin-1 and ETO/MTG8 cofraction-
ated almost exclusively with the insoluble nuclear matrix
fraction. Both endogenous and transgene-derived atro-
phin-1 were associated with this fraction, and all trans-
gene-derived species (full length, high molecular weight
modified species, and truncated forms) associated with
this fraction. A high molecular weight smear of atrophin-1
immunoreactivity was also apparent in the nuclear matrix
preparation, suggesting that aggregated atrophin-1, possi-
bly in inclusions, was also contained in this preparation.
ETO/MTG8 immunoreactivity was not detected at the top
of the wells or in the stacking gel.
Discussion
Recent evidence suggests that DRPLA may be caused by
the accumulation of truncated fragments of atrophin-1 in
specific neuronal nuclei (Schilling et al., 1999). These trun-
cated fragments contain the intact NH2 terminus of atro-
phin-1 (Wood, J.D., unpublished observations). To date,
the function(s) of atrophin-1 in the nucleus are unknown.
We used the yeast two-hybrid system to find proteins that
interact with the NH2 terminus of atrophin-1 and identi-
fied ETO/MTG8, a protein known to be associated with
transcriptional corepressor complexes. ETO/MTG8 coim-
munopurified with atrophin-1 from brain extracts, suggest-
ing that the interaction is physiologically relevant. When
cotransfected into Neuro-2a cells, atrophin-1 and ETO/
MTG8 colocalized in discrete nuclear matrix–associated
structures, which immunostained for the endogenous core-
pressor complex proteins mSin3A, HDAC1, and HDAC2.
Furthermore, atrophin-1 and ETO/MTG8 cofractionated
in the nuclear matrix fraction of mouse brain nuclei. We
also demonstrated that atrophin-1 can repress transcrip-
tion in a reporter gene model system, and that repression
was enhanced by cotransfection with ETO/MTG8. To-
gether, these findings show that atrophin-1 can be a com-
ponent of transcriptional corepressor complexes and may
Figure 6. Expression of ETO/MTG8 recruits atrophin-1 to the
nuclear matrix fraction. (A) Nuclear matrix fractions were pre-
pared from transfected Neuro-2a cells by sequential extraction or
digestion with 0.5% Triton X-100, 250 mM (NH4)2SO4, 300 U/ml
DNase I, and 2 M NaCl. The supernatants from these treatments
and the final matrix preparations were immunoblotted for atro-
phin-1 and FLAG-ETO/MTG8. When transfected alone, most
atrophin-1 was extracted with Triton X-100, although some atro-
phin-1 was associated with the insoluble matrix preparation (top
two rows). When cotransfected with FLAG-ETO/MTG8, a sub-
stantial proportion of atrophin-1 was recruited to the matrix frac-
tion (center two rows), where FLAG-ETO/MTG8 was mainly localized (bottom two rows). (B) Immunocytochemical staining of nu-
clear matrix preparations from transfected Neuro-2a cells in situ. The large structures containing atrophin-1 and FLAG-ETO/MTG8
remained attached to the nuclear matrix whereas the diffuse label observed after routine immunocytochemical staining was washed
away by the extraction procedures.
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be involved in the regulation of gene transcription in the
nucleus. Hence the accumulation of truncated atrophin-1
fragments in specific neuronal nuclei in DRPLA could in-
terfere with transcriptional control and contribute to the
disease phenotype.
ETO/MTG8 was identified as the fusion partner of
AML1 in t(8;21) translocations causing acute myeloid leu-
kemia (Erickson et al., 1992; Nisson et al., 1992; Miyoshi et
al., 1993). ETO/MTG8 contains three proline-rich or pro-
line/serine/threonine–rich regions, the COOH-terminal one
of which contains a PEST sequence (Rechsteiner and
Rogers, 1996), a signal for degradation by the ubiquitin-
proteasome pathway. It also contains two zinc finger-like
motifs (alternatively referred to as the MYND motif; Lut-
terbach et al., 1998a) which interact with N-CoR (Gel-
metti et al., 1998; Lutterbach et al., 1998b; Wang et al.,
1998a). N-CoR is one member of a family of related pro-
teins, including SMRT, and ETO/MTG8 has been shown
to bind to SMRT and mSin3 independently of its interac-
tion with N-CoR (Gelmetti et al., 1998; Lutterbach et al.,
1998b). This may explain why we were able to observe
complexes of atrophin-1, ETO/MTG8, mSin3A, and his-
tone deacetylases in the apparent absence of N-CoR.
ETO/MTG8 is one member of a family of highly con-
served proteins. The other human family members identi-
fied to date are MTGR1 (Kitabayashi et al., 1998) and
MTG16 (Gamou et al., 1998). We isolated a single clone
for MTG16 in our initial two-hybrid screen. Messenger
RNA for ETO/MTG8 is relatively abundant in brain, tes-
tis, and ovary, present at a lower level in heart and lung,
and essentially absent in other tissues examined to date
(Davis et al., 1999; Miyoshi et al., 1993). The expression
patterns of MTGR1 and MTG16 are more widespread
(Gamou et al., 1998; Kitabayashi et al., 1998). ETO/
MTG8, MTGR1, and MTG16 can self-associate and asso-
ciate with each other via a hydrophobic heptad repeat
(Davis et al., 1999; Kitabayashi et al., 1998; Lutterbach et
al., 1998a), suggesting that they may coexist in transcrip-
tional regulatory complexes.
An emerging link between the disease-associated poly-
glutamine proteins is nuclear matrix association. Ataxin-1
and ataxin-3 both have been shown to be associated with
the nuclear matrix (Skinner et al., 1997; Tait et al., 1998).
Ataxin-1 interacts in a polyglutamine tract-length–depen-
dent manner with the cerebellar leucine-rich acidic nu-
clear protein in discrete nuclear matrix-associated struc-
tures (Matilla et al., 1997). Here we demonstrate that both
normal (unexpanded) and various forms of mutant atro-
phin-1 (truncated, full-length, and high molecular weight
modified) are associated with the nuclear matrix. These
forms of mutant atrophin-1 accumulate in DRPLA trans-
genic mice as the phenotype progresses (Schilling et al.,
1999), so it is possible that these nuclear matrix-associated
forms underlie the progression of neuropathology.
In our DRPLA transgenic mice, we see both time-
dependent formation of neuronal intranuclear inclusions
and accumulation of nuclear matrix–associated forms of
atrophin-1. There is a close correlation between the
threshold for polyglutamine aggregation in vitro and the
threshold for polyglutamine diseases in vivo, and macro-
molecular aggregates are a good marker for disease. A
number of publications suggest that cellular dysfunction,
in both cell and animal models, can occur in the absence of
polyglutamine aggregation (Hodgson et al., 1999; Klement
et al., 1998; Saudou et al., 1998). Hence the correlation be-
tween thresholds may merely represent an ability of
expanded polyglutamine proteins to adopt a different
conformation, which leads to altered and novel protein–
protein interactions. In the three studies mentioned above,
nuclear localization of the expanded polyglutamine pro-
tein was required for neurodegeneration. Demonstration
that the neurotoxic expanded polyglutamine proteins are
associated with the nuclear matrix in these other models,
as in our DRPLA model, would strengthen our argument
that dysfunction in the nuclear matrix underlies poly-
glutamine pathogenesis. The ETO chromosomal translo-
cation in AML misdirects AML1 away from its normal
subnuclear domain to alternative subnuclear domains
(McNeil et al., 1999). One could hypothesize that ex-
panded polyglutamine proteins also cause misrouting of
gene regulatory factors in an analogous fashion to translo-
cation-associated leukemias. There may already be a pre-
cedent for this in the case of SCA1, where mutant ataxin-1
has been shown to influence PML localization (Skinner et
al., 1997).
Figure 7. Atrophin-1 and ETO/MTG8 cofractionate with the nu-
clear matrix fraction of DRPLA transgenic mouse brains. Nuclei
were isolated from 6-mo-old AT-FL-65Q-150 DRPLA trans-
genic mice then extracted/digested sequentially with 0.5% Triton
X-100, 250 mM (NH4)2SO4, and 300 U/ml DNase I. The superna-
tants from these treatments and the insoluble matrix fraction
were immunoblotted for atrophin-1 (antibody AP142, top) and
ETO/MTG8 (antibody 2174, bottom). The majority of the immu-
noreactivity for both proteins was associated with the matrix
preparation. The atrophin-1 blot shows a triplet of bands at
around 190–220 kD. The faint lower band (bottom arrow) corre-
sponds to full-length endogenous atrophin-1, the middle band
(center arrow) corresponds to full-length transgene-derived mu-
tant atrophin-1, and the upper band (top arrow) is an expanded
polyglutamine-specific modified form of atrophin-1. The identity
of these bands was ascertained by comparing the banding pat-
terns in extracts from nontransgenic mice, DRPLA transgenic
mice, human DRPLA cerebella, and human control cerebella.
Other high molecular weight species and truncated forms of atro-
phin-1 (the predominate band at z120 kD) were also associated
with the matrix preparation.
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The gene products for five, possibly six, genes mutated
in polyglutamine neurodegenerative disorders can now be
linked to transcriptional control via nuclear receptor sig-
naling. The androgen receptor is a DNA-binding tran-
scription factor that contains an unstable polyglutamine
tract that is expanded in patients with X-linked spinal and
bulbar muscular atrophy (SBMA) or Kennedy’s disease
(La Spada et al., 1991). Here we show that atrophin-1, the
DRPLA gene product, represses transcription and inter-
acts with ETO/MTG8 in nuclear matrix-associated struc-
tures that contain mSin3 and histone deacetylases. ETO/
MTG8 interacts with N-CoR, while N-CoR interacts with
huntingtin, the Huntington’s disease gene product, in a
polyglutamine repeat length–dependent manner (Boutell
et al., 1999). Nuclear receptors such as the retinoic acid re-
ceptor (RARa) and retinoid X receptor (RXRa) can asso-
ciate with PODs. The function of PODs remains enig-
matic, although they may be related to gene transcription
and cell death (Quignon et al., 1998; Wang et al., 1998b).
The spinocerebellar ataxia type 1 and 3 gene products
have both been linked to PODs: mutant ataxin-1 redistrib-
utes PML and colocalizes with PODs to some extent,
whereas mutant ataxin-3 aggregates colocalize with PODs
(Chai et al., 1999; Skinner et al., 1997). We have found that
atrophin-1– and ETO/MTG8-containing nuclear com-
plexes appear to be distinct from PODs, but overexpres-
sion of atrophin-1 and ETO/MTG8 with PML led to ap-
parent redistribution of PML. Unlike with ataxin-1, PML
redistribution was independent of the length of the
glutamine repeat in atrophin-1. It should also be noted
that expansion of the polyglutamine tract in the TATA-
binding protein, a basal transcription factor, may cause
neurological disease (Koide et al., 1999).
It is apparent that the normal function of a number of
the polyglutamine disease proteins may include transcrip-
tional regulation, and there is evidence that altered gene
transcription may be a major cause of cellular dysfunction
in these diseases. Huntington’s disease transgenic mice
show alterations in the levels of mRNA for components of
neurotransmitter, calcium, and retinoid signaling pathways
at early and late symptomatic time points (Cha et al., 1998;
Luthi-Carter et al., 2000), suggesting that transcriptional
regulatory mechanisms are affected in the brains of these
mice. Such effects are not restricted to Huntington’s dis-
ease as polyglutamine expansion in ataxin-1 downregulates
specific neuronal genes before pathologic changes occur in
SCA1 mice (Lin et al., 2000). Part of each disease pheno-
type could reflect interference with the normal function of
each polyglutamine protein. However, all of the poly-
glutamine diseases show autosomal dominant inheritance,
suggesting that these diseases are caused by novel gains of
function of the expanded polyglutamine proteins, and not
simply losses of function. Consistent with such a mecha-
nism, we have found that mutant expanded huntingtin and
atrophin-1, but not the normal unexpanded proteins, se-
quester CBP and interfere with CBP-mediated transcrip-
tion, which adversely effects neuronal survival (Nucifora,
F.C., Jr., M. Sasaki, M.F. Peters, H. Huang, J. Troncoso,
V.L. Dawson, T.M. Dawson, and C.A. Ross, manuscript
submitted for publication). This type of mechanism could
be common to the polyglutamine disorders and distinct
from the normal transcriptional role of each protein.
In summary, we have shown that atrophin-1 interacts
with ETO/MTG8, that atrophin-1– and ETO/MTG8-con-
taining complexes are associated with the nuclear matrix,
and that atrophin-1 can repress transcription. These find-
ings shed considerable new light on the function of atro-
phin-1 in the nucleus and may also be relevant to patho-
logical neuronal dysfunction in DRPLA. The emerging
links between the neurodegenerative disease–associated
polyglutamine proteins, translocation-leukemia proteins,
nuclear receptor corepressor complexes, and the nuclear
matrix may have wider repercussions for the whole family
of polyglutamine diseases.
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